Cancer link casts pall over CRISPR
Reports suggesting that CRISPR could cause cancer dinged the stock prices of the big three gene editing companies: Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics all fell by 10 percent or more.
The findings: CRISPR is all about cutting DNA—but cells don’t like that very much. Two papers in the journal Nature Medicine (here and here) found that the damage cause by CRISPR can kill cells or stop them from growing.
The problem: CRISPR is a lot less likely to kill cells with defective versions of a gene called p53, whose anticancer role has led some to call it the guardian of the genome. In short, CRISPR could give a survival advantage to cells likely to turn cancerous, according to Stat.
The upshot: The new findings could help explain why the U.S. Food & Drug Administration placed a planned human study by CRISPR Therapeutics on hold in May. That company has hoped to use CRISPR as a gene therapy to treat sickle-cell disease.
Deep Dive
Biotechnology and health
This baby with a head camera helped teach an AI how kids learn language
A neural network trained on the experiences of a single young child managed to learn one of the core components of language: how to match words to the objects they represent.
An AI-driven “factory of drugs” claims to have hit a big milestone
Insilico is part of a wave of companies betting on AI as the "next amazing revolution" in biology
How scientists traced a mysterious covid case back to six toilets
When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.
The next generation of mRNA vaccines is on its way
Adding a photocopier gene to mRNA vaccines could make them last longer and curb side effects.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.